The present data give new insights into the mechanisms by which clenbuterol exerts its preventive effect on muscle protein waste and seem to warrant the implementation of experimental protocols involving the use of clenbuterol or alike drugs in the treatment of pathological states involving TPH, particularly in skeletal muscle and heart, such as in the present model of cancer cachexia. (J. Clin. Invest. 1995Invest. . 95:2367Invest. -2372
Introduction
Malignant neoplasms frequently induce a progressive loss of lean body mass in the host associated with marked alterations in the endocrine and metabolic homeostasis. The skeletal muscle, which accounts for almost half of the whole body protein mass, is severely affected in cancer cachexia ( 1-3 ) and evidence has been provided for muscle protein waste as being associated with enhanced turnover rates (4) (5) (6) (7) (8) (9) . Since cachexia tends to develop at a rather advanced stage of the neoplastic growth, preventing muscle waste in cancer patients is of a great potential clinical interest. Whether the negative protein balance results from altered rates of synthesis or breakdown or from changes on both sides of muscle protein turnover is still debated, however (6, (10) (11) (12) .
The rat ascites hepatoma Yoshida AH-130 is a suitable model system to study the mechanisms involved in the establishment of cachexia. Its growth causes in the host rapid and progressive loss of body weight and tissue waste, particularly in skeletal muscle. Acceleration of tissue protein breakdown accounts for most of the waste in the AH-130 bearers (6, [13] [14] [15] . In particular, skeletal muscle hypercatabolism is mainly due to hyperactivation of the ATP-ubiquitin-dependent proteolytic system (16) . Detectable plasma levels of tumor necrosis factor-a (TNF) and perturbations in the hormonal homeostasis (17) likely play an important role in forcing the metabolic balance towards the catabolic side.
/32-adrenergic agonists are potent muscle growth promoters in many animal species ( 18) , resulting in skeletal muscle hypertrophy, while they cause a reduction of the body fat content (19) . These compositional alterations are associated with a redistribution of energy substrates, which are mobilized from storage sites for utilization by tissues such as muscle and brown adipose tissue (19) . The intimate mechanisms by which these compounds exert such effects at the cellular level are still uncertain (19) , although changes in protein turnover are clearly involved. Little is known, however, as to whether /2-agonists act by potentiating the anabolic processes or depressing the catabolic ones.
Aim of the present investigation has been to study the effects 
Results
The rat ascites hepatoma Yoshida AH-130 grew exponentially for 4-5 d then shifted into a stationary phase approximately by day 8 after transplantation, as previously shown (29) . This growth pattern was not significantly affected by clenbuterol (Table I) .
Clenbuterol did not alter the food intake either in controls or in tumor bearers. The hypophagia occurring during tumor growth (15, 17) persisted unchanged in treated animals: the average daily food intake was 25 and 23 g on day 0, and 14, and 15 g on day 8 after tumor inoculation, respectively, in untreated and treated tumor hosts; in treated and untreated nontumor bearing animals it amounted to 24 and 23 g, respectively, over the whole experimental period.
As shown in Table I , the loss of body weight in tumor bearers became prominent by day 8 and was not affected by clenbuterol. A marked reduction of white adipose tissue mass was already detectable at day 4 in clenbuterol-treated controls; this tissue was also diminished in day 8 tumor bearers, yet not further affected to a significant degree by the drug treatment. Both liver and brown adipose tissue were hypotrophic 4 d after tumor inoculation and even more so by day 8; no significant protective effect was exerted by clenbuterol on either tissue.
Quite different was the pattern with regard to skeletal and heart muscles. An early and progressive decrease in wet weight (data not shown) and protein content was elicited by tumor growth (Table H) , with gastrocnemius and heart being affected earlier and more severely than soleus, as previously reported (6). Treatment with clenbuterol substantially prevented the protein waste in each tissue, since day 4 for gastrocnemius and heart, by day 8 for the soleus. This protective effect was also noticeable in terms of wet tissue weight for the skeletal muscles, but not for the heart (data not shown); a similar discrepancy between heart wet weight and protein content had already been observed in AH-130 tumor bearers treated with anti-TNF antibodies (30) . In agreement with previous observations, clenbu- terol afforded a significant trophic action (protein increase) on muscles in nontumor bearers as well, particularly on the gastrocnemius and less on the heart, while the soleus was not significantly affected (Table H) . Protein turnover in gastrocnemius and heart was evaluated to assess by which regulation, whether on synthesis or on degradation or both, the protein-sparing action of clenbuterol was exerted. As previously reported (6, 15), rates of protein degradation were enhanced in both muscles examined in consequence of tumor growth, while synthesis remained virtually unchanged, resulting in protein accumulation rates lower than in controls (Table HI) . On treatment with clenbuterol, the elevation of protein breakdown rates was suppressed and protein accumulation rates returned similar to those in controls (Table HI) . No detectable effect was observed with regard to protein synthesis rates. Likewise in nontumor bearers, the gastrocnemius and heart hypertrophy observed on drug treatment appeared to result from a marked decrease in protein catabolic rates, while synthesis rates were not significantly affected (Table III) .
As previously shown (16) , the accelerated muscle protein breakdown in the AH-130 hosts may be achieved through activation of the ATP-ubiquitin-dependent proteolytic system. As (Fig. 1) .
Corticosterone was elevated and insulin decreased in the blood plasma of AH-130 hosts, as previously observed (17) . When these animals were administered clenbuterol, neither insulin nor corticosterone changes were affected, suggesting that the drug effects were not mediated through these hormones. In nontumor bearers the treatment did not modify corticosterone, while insulin concentrations decreased below the control values (Table IV) .
Discussion
Muscle protein waste is a main feature in cancer cachexia and, generally, is mostly ascribed to enhanced tissue protein catabolism (4-9, 15). So far, most therapeutic approaches to cancer cachexia have been designed on the assumption that tissue waste merely results from undernutrition or tumor-host competition, yet parenteral nutrition or overfeeding have proven to be only marginally or, at best, temporarily effective (31-33). Moreover, in some cases the tumor itself apparently took advantage of such regimen more than the patient (32, 34) .
The rat tumor model used in the present study quickly causes progressive body weight loss and tissue protein waste, the latter associated with TPH (6, 15) likely mediated by production of cytokines such as TNF and alterations in the hormonal homeostasis (17) . The beneficial effects of treatments with anti-TNF antibodies (30) or with drugs interfering with the development of TPH (35) For further details see Methods section. Fractional rates of protein synthesis (k,), degradation (kd) and accumulation (ka) are expressed as percent per day (n = S for each time point) and were calculated over the time interval 0-8 d, since linearity of radioactivity decay during the experimental period (days 0-2-4-6-8) was tested. Variance between groups is indicated by SE of the slope (t X SE of the slope, t being the 95% value of student's t test for n-2 (see Lee and Lee) (28). Significance of the differences: ** P < 0.01 vs. controls; * P < 0.05 and 11 P < 0.01 vs. AH-130.
tions. Thus clenbuterol markedly attenuates the muscle atrophy by denervation (36, 37) or by hindlimb suspension (38) . Moreover, this drug can increase the skeletal muscle mass in mice with genetic muscle dystrophy (39) . More recently, clenbuterol has been reported to accelerate the recovery of the skeletal muscle mass after challenge with bacterial lipopolysaccharides or surgical stress (40, 41 ) . It is not clear how these agents modulate tissue protein turnover, though some indirect evidence for an effect on protein catabolism has been provided. Reeds et al. (42) did not observe any change in the gastrocnemius protein synthesis rates after dietary administration of clenbuterol to rats, and concluded that decreased breakdown had to be involved. An indirect confirmation that /2-agonists may act by reducing protein catabolism came from a recent study in which the intracellular amino acid content of rat gastrocnemius was shown to increase after treatment with metaproterenol (43) . In addition, glutamine, and alanine were found to be released at reduced rates from isolated muscles in the presence of the,3-adrenergic agonist isoprenaline (44) . The present study is totally consistent with these previous reports. Both the prevention of muscle protein depletion in AH-130 tumor bearers and the increase of muscle protein mass in nontumor bearers afforded by clenbuterol appeared to result from regulations on the catabolic side, respectively, by restoring protein breakdown to normal rates or by reducing them to less than normal levels. Moreover, in agreement with previous reports (45, 46) , the effects of the drug appeared more marked on a fast-twitch (gastrocnemius) than on a slow-twitch muscle (soleus). The trophic action of 62-adrenergic agonists is generally regarded as quite selective for the skeletal muscle (19, 38, 42) . After treatment with such drugs, however, cardiac hypertrophy has been reported in some studies (42, 47), yet not in others (38) . In the present study, clenbuterol administration exerted quite comparable effects on gastrocnemius and heart in both control and tumor-bearing animals.
The precise mechanisms by which intracellular proteins are degraded is largely unknown, although it is accepted that proteolysis may occur inside and outside the lysosomes. Lysosomic proteases, in particular cathepsins, do not seem to be largely involved in the degradation of myofibrillar proteins in rat skeletal muscle (35, 48) . The ATP-ubiquitin-dependent proteolytic system is postulated to account for the turnover of short-lived proteins (49) or for abnormal proteins formed during stress such as heat-shock (50). However, it has been suggested that the activity of this system can also be related to the turnover of long-lived proteins such as those found in skeletal muscle (51) . Recently, this proteolytic system has been involved in the perturbations of protein metabolism consequent to fasting and denervation atrophy (52). Previous studies from our laboratory have shown that the lysosomal pathway is only marginally involved in the development of muscle protein hypercatabolism in the AH-130 hosts (16, 35) , while an important activation of the ATP-dependent proteolysis seems to be the leading mechanism (16) . It is very interesting to observe that the preventive effect exerted by clenbuterol on the acceleration of muscle protein breakdown is due to complete repression of the hyperexpression of the ubiquitin mRNAs. The association between the increased ubiquitin gene expression and the proteolytic activity in this tumor model has been recently studied by our laboratory (53) . Moreover, it is important to underline that in control rats receiving clenbuterol, the ubiquitin mRNAs expression is below the basal value. To the best of our knowledge, this is the first report showing that the effect of clenbuterol on muscle protein turnover is due to down-regulation of the ATP-ubiquitin-dependent proteolytic system. 32-adrenergic agonists are also known to display their anabolic effects in different situations of perturbed endocrine status such as diabetes, adrenalectomy, or castration (47, 54) , suggesting that their action might involve hormonal modulations. However, as far as insulin and corticosterone are concerned, the present study suggests that this is not the case for the AH-130 hosts, since the altered plasma level of neither hormone was corrected by the treatment. However, the hormonal involvement (56) . In addition, these drugs enhance the overall energy expenditure and increase the thermogenesis, thereby dissipating the excess energy derived from the lipids mobilized (19) . The present cachexia model in itself is characterized by extensive lipid mobilization (20, 57) , associated with decreased activity of tissue lipoprotein lipase (20). The lack of effect of clenbuterol on adipose tissue in AH-130 hosts thus probably reflects the fact that lipid mobilization was already occurring in these animals and could not be easily stimulated further. When the drug treatment was applied to control rats, however, the adipose tissue mass decreased with respect to untreated controls (by 20%), in agreement with previous reports (38, 58) .
In conclusion, the present results indicate that clenbuterol 
